The National Company Law Appellate Tribunal (NCLAT), by its order dated 30 October 2025, dismissed an appeal challenging an order of the Competition Commission of India (CCI) closing a case...
NCLAT RULES THAT CCI HAS NO POWER TO INVESTIGATE PATENT
DISPUTES
The National Company Law Appellate Tribunal (NCLAT), by its
order dated 30 October 2025, dismissed an appeal challenging an
order of the Competition Commission of India (CCI) closing a case
against Vifor International (AG) under Section 26(2) of the
Competition Act, 2002 (Act).
The appellant, CEO of a hospital providing dialysis services
under a government programme, had alleged that Vifor International,
the Swiss developer and patent holder of the drug Ferric
Carboxymaltose (FCM) used in treating iron deficiency anaemia, is
engaged in anticompetitive practices by limiting access and keeping
prices high. It was alleged that Vifor's exclusive licensing
arrangements with Emcure Pharmaceuticals Ltd. and Lupin Ltd.
violated Sections 3 and 4 of the Act.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.